Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $22.59B), while Inovio Pharmaceuticals Inc trades at $1.18 (market cap $101.95M). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 221.6× Inovio Pharmaceuticals Inc's market cap, and Liberty Media Corporation Series C Liberty Formula One Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FWONK | INO | |
|---|---|---|
Market Cap | $22.59B | $101.95M |
Volume | 2,257,903 | 2,985,847 |
Sector | Media | Health |
52-Week High | $106.66 | $2.60 |
52-Week Low | $81.42 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $26.05B | $73.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.
INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
